Dr. Sax is director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital (BWH) in Boston. He has taught at Harvard Medical School for more than 14 years and is currently an associate professor of medicine there. Dr. Sax received his M.D. from Harvard Medical School in 1987. He fulfilled his residency in Internal Medicine at BWH, while continuing his postdoctoral education with fellowships at Harvard and the Infectious Disease Unit of Massachusetts General Hospital. Dr. Sax is board certified in Internal Medicine and Infectious Disease. Apart from his clinical and teaching work, Dr. Sax is also involved in many professional societies, such as the Massachusetts Medical Society, the Infectious Disease Society of America, and the Massachusetts Infectious Disease Society. He serves on the editorial board of AIDS Clinical Care, Infectious Diseases Special Edition, UpToDate and Medscape. He is on the core faculty of the International AIDS Society-USA and the New England AIDS Education and Training Center. Dr. Sax is also a regular contributor to HIV and ID Observations, a NEJM Journal Watch blog.
Dr. Sax has been a consultant for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences and GlaxoSmithKline. He has received research support from Pfizer, Inc. and GlaxoSmithKline. In addition, he receives teaching honoraria from Abbott Laboratories, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck & Co. and Tibotec.
Do the guidelines for laboratory monitoring still make sense when our HIV treatments have become so safe and effective? Paul E. Sax, M.D., offers a revised -- and deliberately provocative -- recommendation.
Paul Sax, M.D., puts it bluntly: "[I]t makes zero sense to do this since the babies aren't at risk of getting HIV to begin with."
Just in time for Thanksgiving, Paul Sax, M.D., provides a rundown of developments that infectious disease and HIV specialists can be grateful for over the past year.
Paul Sax, M.D., provides a rundown of the research that caught his attention at this year's IDWeek conference.
"Since this appears to be a 'best in class' drug, doravirine has enough advantages that it is a useful advance in HIV therapy, if not a transformational one," writes Paul Sax, M.D.
Paul Sax, M.D., provides highlights of the important and interesting studies that caught his eye at AIDS 2018.
Paul Sax, M.D., says that while most patients prefer the simplicity of having one pill, one prescription, and one co-pay, the new Symtuza (D/C/F/TAF) tablet faces several challenges that may limit widespread adoption.
Earlier this year, urology resident Philip Cheng, M.D., appeared on the front page of The New York Times explaining his situation. Now, in a podcast, he tells Paul Sax, M.D., more about himself and the events surrounding his decision to go public....
There are several reasons why this warning is important -- and why the best treatment for women with HIV who want children remains an open question.